Biotin-DOTA Conjugates for Stable Radionuclide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biotin-DOTA conjugates face challenges in selective delivery of radionuclides to tumor cells due to resistance to biotinidases, instability in vivo, and potential release of toxic radionuclides, which can damage healthy cells.
Innovation Solution
Development of new biotin derivatives with two chelating groups per molecule, specifically designed to enhance the radiation/dose ratio by doubling the radioactivity reaching tumor cells while maintaining stability and minimizing uptake by non-tumor cells, using a formula (I) compound structure that includes various alkylene, alkenylene, and aromatic residues for improved targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biotin-DOTA conjugates are used to deliver radionuclides to tumor cells, then targeting capability is improved, but resistance to biotinidases causes instability and potential release of toxic radionuclides
Solution Approach 1:
The patent extracts the vulnerable amide bond from the conjugate structure by reducing it to a methylene bridge, thereby removing the peptide bond that biotinidases target. This structural modification eliminates the enzymatic cleavage site while preserving the functional connectivity between biotin and DOTA.
Solution Approach 2:
The invention creates a composite structure where biotin is chemically modified to form a reduced biotinamido derivative. This composite molecule combines the tumor-targeting capability of biotin with the stable chelating properties of DOTA, while the reduced linkage provides enzymatic resistance.
2Power
If conventional biotin-DOTA conjugates are used, then radionuclide delivery to tumors is achieved, but the radiation/dose ratio is insufficient due to single chelating group limitation
Solution Approach 1:
The patent merges two DOTA chelating groups onto a single reduced biotinamido derivative core, creating a bivalent conjugate structure. This combination allows dual radionuclide attachment to one targeting molecule, effectively doubling the radiation payload delivered per tumor cell binding event.
Solution Approach 2:
The reduced biotinamido derivative serves multiple functions simultaneously: it provides tumor cell targeting through intact biotin moieties, stabilizes two radionuclides through dual DOTA chelators, and resists enzymatic degradation through its reduced linkage structure.
3Reliability
If the complex is made larger to improve stability, then resistance to biotinidases increases, but molecular weight increases reducing renal clearance
Solution Approach 1:
The patent applies local structural modification only at the critical linkage region (reducing the amide bond to methylene) rather than throughout the entire molecule. This localized change provides enzymatic resistance without adding significant molecular weight, preserving the overall compact structure for efficient renal clearance.
Data Source
AI summary
Formula (I) compounds are described: Formula (I) where the radicals are as defined in the description, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.